<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17478" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Amphetamine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Martin</surname>
            <given-names>Dustin</given-names>
          </name>
          <aff>LECOM</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Le</surname>
            <given-names>Jacqueline K.</given-names>
          </name>
          <aff>Desert Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Dustin Martin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jacqueline Le declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>31</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17478.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Amphetamine is a medication used in the management and treatment of ADHD and narcolepsy. It is classified as a central nervous system stimulant. This activity reviews the indications, action, and contraindications for amphetamine as an agent in treating ADHD and narcolepsy. This activity will highlight the mechanism of action, adverse effect profile, and other key factors (e.g., dosing, monitoring, toxicity) pertinent for members of the interprofessional team in the treatment of patients with ADHD and narcolepsy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Explain the mechanism of action of amphetamine.</p></list-item><list-item><p>Describe the potential adverse effects of amphetamine.</p></list-item><list-item><p>Identify signs and symptoms of amphetamine toxicity.</p></list-item><list-item><p>Review the importance of collaboration and communication amongst the interdisciplinary team to properly monitor for adverse effects in patients receiving amphetamine treatment.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17478&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17478">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17478.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Amphetamine is FDA-approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. It has indications as a first-line agent for ADHD in adults and children six years of age and older. Amphetamine is also a second-line agent for the treatment of narcolepsy. Lisdexamfetamine, a long-acting amphetamine medication, is FDA-approved for the treatment of a binge-eating disorder.&#x000a0;</p>
        <p>The amphetamine molecule contains one chiral center and exists as two enantiomers: dextroamphetamine (d-amphetamine) and levoamphetamine (l-amphetamine). The term &#x0201c;amphetamine&#x0201d; properly refers to a racemic mixture of equal parts d-amphetamine and l-amphetamine. However, most currently used amphetamine medications contain the d-isomer predominantly or exclusively as it is more potent and more clinically effective than the l-isomer.<xref ref-type="bibr" rid="article-17478.r1">[1]</xref></p>
        <p>Common amphetamine medications that are currently in use in the United States include<xref ref-type="bibr" rid="article-17478.r2">[2]</xref>:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Dextroamphetamine/amphetamine, a 3 to 1 mixture of d-amphetamine and l-amphetamine salts, otherwise known as mixed amphetamine salts (MAS)</p>
          </list-item>
          <list-item>
            <p>Dextroamphetamine, a drug containing none of the l-isomer</p>
          </list-item>
          <list-item>
            <p>Lisdexamfetamine, an inactive prodrug that is converted into d-amphetamine in the bloodstream</p>
          </list-item>
        </list>
        <p>Amphetamines are controlled substances in the USA with the C-II designation.</p>
      </sec>
      <sec id="article-17478.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Amphetamine is a central nervous (CNS) system stimulant that functions by increasing the amounts of dopamine, norepinephrine, and serotonin (to a lesser extent) in the synaptic cleft through a variety of mechanisms. Amphetamine enters the presynaptic axon terminal through diffusion or uptake by the monoamine transporters DAT, NET, and SERT. Once inside the presynaptic terminal, amphetamine increases&#x000a0;the amounts&#x000a0;of monoamine neurotransmitters&#x000a0;in the cytosol through the inhibition of vesicular monoamine transporter 2 (VMAT2) as well as through disruption of the electrochemical gradients necessary for vesicular transporter function.</p>
        <p>Amphetamine also inhibits the metabolism of monoamine neurotransmitters by inhibiting monoamine oxidase (MAO). At the same time, amphetamine stimulates the intracellular receptor TAAR1, which induces internalization or transporter reversal of DAT. The effects of TAAR1 on DAT may also extend to NET and SERT, although co-localization of TAAR1 with these two transporters has only been indirectly evidenced in studies thus far. The net result of this activity is increased efflux of dopamine into the synaptic cleft and reuptake inhibition in the synaptic cleft through DAT internalization and direct competition.<xref ref-type="bibr" rid="article-17478.r3">[3]</xref><xref ref-type="bibr" rid="article-17478.r4">[4]</xref></p>
      </sec>
      <sec id="article-17478.s4" sec-type="Administration">
        <title>Administration</title>
        <p>The choice of agent for initial therapy is based on cost, patient preference, and concern for abuse. Dextroamphetamine is the only amphetamine medication FDA-approved for use in children younger than six years, but most current guidelines recommend behavioral therapy alone in preschool-aged children with ADHD symptoms.<xref ref-type="bibr" rid="article-17478.r5">[5]</xref>&#x000a0;Dextroamphetamine is available in the form of immediate-release tablets, extended-release capsules, and an oral solution. MAS is available as immediate-release tablets or extended-release capsules. Immediate-release formulations may be preferred initially to establish an optimal daily dose, with conversion to an extended-release formulation thereafter. Extended-release formulations are intended for once-daily dosing, but they may require concomitant use of an immediate-release medication as the clinical effect wears off in the afternoon.<xref ref-type="bibr" rid="article-17478.r6">[6]</xref>&#x000a0;Patients with narcolepsy generally benefit from divided doses and may require an early afternoon dose to control daytime sleepiness.</p>
        <p>Dosages usually range from 5 mg to 40 mg daily and should not exceed 60 mg, which is the maximum dose for certain adults.<xref ref-type="bibr" rid="article-17478.r7">[7]</xref> Dosing by indication is as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>ADHD: 5 to 40 mg daily divided from one to three doses - divided doses should be at 4 to 6-hour intervals. Doses exceeding 40 mg are rarely more effective.</p>
          </list-item>
          <list-item>
            <p>Narcolepsy: 5 to 60 mg daily divided from one to three doses; start with 10 mg each morning, increasing dose by 10 mg daily each week; divided doses should be at 4 to 6-hour intervals. Prolonged, high-dose use should be stopped.</p>
          </list-item>
          <list-item>
            <p>Obesity (short-term treatment): 15 to 30 mg daily divided into three doses, given 30 to 60 minutes before meals. Discontinuation should be tapered. Discontinue prolonged high-dose use.</p>
          </list-item>
        </list>
        <p>Lisdexamfetamine may be preferred if there is increased concern for misuse by the patient or a household member, as its chemically-phased release allows for once-daily dosing and may theoretically deter abuse. Lisdexamfetamine is available as&#x000a0;capsules or chewable tablets, and typical daily&#x000a0;dosages range from 20 mg to 70 mg.</p>
      </sec>
      <sec id="article-17478.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Reports exist of slowing growth velocity and reduction in adult height in patients who took stimulants as children, with an average adult height deficit of 4.7 cm among patients who consistently took the medication. This stunted growth appears to be primarily a consequence of reduced appetite and caloric intake associated with stimulant medications.<xref ref-type="bibr" rid="article-17478.r8">[8]</xref><xref ref-type="bibr" rid="article-17478.r9">[9]</xref></p>
        <p>The association between amphetamine and severe cardiovascular events is controversial. There have been reports of severe cardiovascular events such as myocardial infarction and sudden cardiac death in patients (including children) treated with stimulants. These reports led to the temporary suspension of marketing for extended-release MAS in Canada in 2005 and proposals for an FDA boxed warning in the United States. Some reported cases involved patients with underlying structural cardiovascular abnormalities and/or patients who took supratherapeutic doses of the medication.<xref ref-type="bibr" rid="article-17478.r10">[10]</xref>&#x000a0;Several large follow-up studies have failed to demonstrate an increased risk of severe cardiovascular events in patients treated with stimulant medications.<xref ref-type="bibr" rid="article-17478.r11">[11]</xref><xref ref-type="bibr" rid="article-17478.r12">[12]</xref></p>
        <p>The use of amphetamine with other serotonergic agents and/or CYP2D6 inhibitors (including fluoxetine, paroxetine, and bupropion) can increase the risk of serotonin syndrome. Amphetamine should be started cautiously in patients taking these medications, with&#x000a0;close monitoring for signs and symptoms of serotonin syndrome.&#x000a0;</p>
        <p>Other common side effects of amphetamine include insomnia, headache, dry mouth, tachycardia, increase in systolic blood pressure, restlessness, and irritability.&#x000a0;</p>
      </sec>
      <sec id="article-17478.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Amphetamine is contraindicated in patients with hypersensitivity to any component of the drug formulation. Amphetamine is also contraindicated during or within 14 days of MAOI therapy, e.g., phenelzine, due to the risk of hypertensive crisis.<xref ref-type="bibr" rid="article-17478.r13">[13]</xref> Additional contraindications include symptomatic cardiovascular disease, advanced arteriosclerosis, glaucoma, hyperthyroidism, severe hypertension, agitated states, and a history of drug misuse.</p>
      </sec>
      <sec id="article-17478.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Cardiac status should have an assessment before initiating therapy in patients with known cardiac abnormalities. Patients with exertional chest pain, shortness of breath, pathologic heart murmurs, or any other signs and symptoms suggestive of cardiac disease should undergo full cardiac assessment, as should any patients with a family history of cardiomyopathy, arrhythmias, or ECG abnormalities such as long QT syndrome. If a baseline ECG reveals a concern, amphetamine should be prescribed with caution after a cardiology referral. Cardiac monitoring should occur on at least an annual basis, and concerning signs include pulse or blood pressure &#x0003e;95th percentile for age and the presence of any cardiovascular symptoms. Growth parameters require monitoring for pediatric patients.<xref ref-type="bibr" rid="article-17478.r14">[14]</xref> Clinicians should also monitor for signs of abuse, diversion, and addiction in all patients.</p>
      </sec>
      <sec id="article-17478.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Due to their ability to produce powerful euphoric effects, amphetamines are common drugs of abuse. All major drugs of abuse increase dopamine concentrations in the mesolimbic pathway, but amphetamines, because of their direct effects on DAT and VMAT2, can increase dopamine concentrations far beyond the concentrations seen for natural rewarding stimuli. Chronic exposure&#x000a0;to amphetamine, particularly methamphetamine, at recreational doses has shown to destroy dopaminergic terminals in the striatum through a variety of mechanisms, including oxidative stress and excitotoxicity. The resultant blunting of the physiological dopamine response can further potentiate abuse.<xref ref-type="bibr" rid="article-17478.r15">[15]</xref><xref ref-type="bibr" rid="article-17478.r16">[16]</xref></p>
        <p>Common signs and symptoms of acute amphetamine intoxication include hypertension, tachycardia, tachypnea, hyperthermia, mydriasis, tremors, agitation, and psychosis. The presentation can be highly variable depending on the amphetamine analog used as well as the simultaneous use of other substances. Dextroamphetamine and methamphetamine have a higher affinity for DAT, and intoxication can cause psychiatric disturbances resembling a manic episode or an acute psychotic break. Other illicit amphetamine analogs such as MDMA have a higher affinity for NET and SERT and are potentially more likely to cause hyperthermia, serotonin syndrome, and rhabdomyolysis. The risk of hyperthermia and rhabdomyolysis may become compounded by the association of MDMA use in dance clubs.<xref ref-type="bibr" rid="article-17478.r15">[15]</xref><xref ref-type="bibr" rid="article-17478.r17">[17]</xref></p>
        <p>Management of amphetamine intoxication generally involves the use of benzodiazepines and antipsychotics to control agitation and psychotic symptoms. Beta-blockers can also help to control hypertension and tachycardia. Intravenous nitrates may be necessary in cases of severe hypertension. Severely agitated patients may require paralysis and intubation, and hyperthermia is manageable with ice packs and evaporative cooling techniques.<xref ref-type="bibr" rid="article-17478.r18">[18]</xref></p>
      </sec>
      <sec id="article-17478.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Amphetamine has high misuse/abuse potential. All&#x000a0;interprofessional team members&#x000a0;(clinicians, nurses, pharmacists, behavioral therapists) involved in the care of a patient taking amphetamines should monitor closely for signs of medication misuse. As a schedule II controlled substance, there are no refills for amphetamine, which may necessitate monthly appointments with the prescribing physician. A cardiologist consult may be necessary for evaluating patients with potential cardiac concerns before the initiation of amphetamines. A pediatrician should monitor growth charts for children taking these medications. Pharmacists should monitor prescribing patterns and warn clinicians of potential doctor shopping". Nursing staff can counsel the patient on proper dosing and administration, warn about side effects, and answer patient questions, which the pharmacist can also reinforce. Interprofessional coordination and open information sharing will optimize amphetamine therapy for those patients who need it, prevent drug abuse and misuse, and prevent adverse outcomes. [Level 5]</p>
      </sec>
      <sec id="article-17478.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17478&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17478">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17478/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17478">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17478.s11">
        <title>References</title>
        <ref id="article-17478.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heal</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Gosden</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nutt</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Amphetamine, past and present--a pharmacological and clinical perspective.</article-title>
            <source>J Psychopharmacol</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>479</fpage>
            <page-range>479-96</page-range>
            <pub-id pub-id-type="pmid">23539642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17478.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ermer</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Pennick</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Frick</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy.</article-title>
            <source>Clin Drug Investig</source>
            <year>2016</year>
            <month>May</month>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>341</fpage>
            <page-range>341-56</page-range>
            <pub-id pub-id-type="pmid">27021968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17478.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nickell</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Siripurapu</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Vartak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Crooks</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Dwoskin</surname>
                <given-names>LP</given-names>
              </name>
            </person-group>
            <article-title>The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.</article-title>
            <source>Adv Pharmacol</source>
            <year>2014</year>
            <volume>69</volume>
            <fpage>71</fpage>
            <page-range>71-106</page-range>
            <pub-id pub-id-type="pmid">24484975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17478.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity.</article-title>
            <source>J Neurochem</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>116</volume>
            <issue>2</issue>
            <fpage>164</fpage>
            <page-range>164-76</page-range>
            <pub-id pub-id-type="pmid">21073468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17478.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Subcommittee on Attention-Deficit/Hyperactivity Disorder</collab>
              <collab>Steering Committee on Quality Improvement and Management</collab>
              <name>
                <surname>Wolraich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>DuPaul</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Earls</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Ganiats</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Kaplanek</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Perrin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pierce</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Reiff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Visser</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents.</article-title>
            <source>Pediatrics</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>128</volume>
            <issue>5</issue>
            <fpage>1007</fpage>
            <page-range>1007-22</page-range>
            <pub-id pub-id-type="pmid">22003063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17478.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daughton</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kratochvil</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls.</article-title>
            <source>J Am Acad Child Adolesc Psychiatry</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>48</volume>
            <issue>3</issue>
            <fpage>240</fpage>
            <page-range>240-248</page-range>
            <pub-id pub-id-type="pmid">19242289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17478.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gautam</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Prabhakar</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Stimulant Formulations for the Treatment of Attention-Deficit/Hyperactivity Disorder.</article-title>
            <source>Prim Care Companion CNS Disord</source>
            <year>2018</year>
            <month>Dec</month>
            <day>27</day>
            <volume>20</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">30605269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17478.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richardson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Seibert</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Uli</surname>
                <given-names>NK</given-names>
              </name>
            </person-group>
            <article-title>Growth perturbations from stimulant medications and inhaled corticosteroids.</article-title>
            <source>Transl Pediatr</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>237</fpage>
            <page-range>237-247</page-range>
            <pub-id pub-id-type="pmid">29184805</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17478.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berman</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Kuczenski</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McCracken</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>London</surname>
                <given-names>ED</given-names>
              </name>
            </person-group>
            <article-title>Potential adverse effects of amphetamine treatment on brain and behavior: a review.</article-title>
            <source>Mol Psychiatry</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>123</fpage>
            <page-range>123-42</page-range>
            <pub-id pub-id-type="pmid">18698321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17478.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sichilima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rieder</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Adderall and cardiovascular risk: A therapeutic dilemma.</article-title>
            <source>Paediatr Child Health</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>193</fpage>
            <page-range>193-5</page-range>
            <pub-id pub-id-type="pmid">20190905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17478.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cooper</surname>
                <given-names>WO</given-names>
              </name>
              <name>
                <surname>Habel</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Sox</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Arbogast</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Cheetham</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Callahan</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Fireman</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Fish</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Kirshner</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>O'Duffy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Connell</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>ADHD drugs and serious cardiovascular events in children and young adults.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>Nov</month>
            <day>17</day>
            <volume>365</volume>
            <issue>20</issue>
            <fpage>1896</fpage>
            <page-range>1896-904</page-range>
            <pub-id pub-id-type="pmid">22043968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17478.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schelleman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bilker</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Strom</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Kimmel</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Newcomb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guevara</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Daniel</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Cziraky</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Hennessy</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular events and death in children exposed and unexposed to ADHD agents.</article-title>
            <source>Pediatrics</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>127</volume>
            <issue>6</issue>
            <fpage>1102</fpage>
            <page-range>1102-10</page-range>
            <pub-id pub-id-type="pmid">21576311</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17478.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feinberg</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>65</volume>
            <issue>11</issue>
            <fpage>1520</fpage>
            <page-range>1520-4</page-range>
            <pub-id pub-id-type="pmid">15554766</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17478.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leonard</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Hines</surname>
                <given-names>EQ</given-names>
              </name>
            </person-group>
            <article-title>Toxicity of acute exploratory amphetamine-salt medication in amphetamine-na&#x000ef;ve pediatrics: a retrospective cohort study.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>58</volume>
            <issue>9</issue>
            <fpage>907</fpage>
            <page-range>907-912</page-range>
            <pub-id pub-id-type="pmid">31913713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17478.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steinkellner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Freissmuth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sitte</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine.</article-title>
            <source>Biol Chem</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>392</volume>
            <issue>1-2</issue>
            <fpage>103</fpage>
            <page-range>103-15</page-range>
            <pub-id pub-id-type="pmid">21194370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17478.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamamoto</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Moszczynska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gudelsky</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Amphetamine toxicities: classical and emerging mechanisms.</article-title>
            <source>Ann N Y Acad Sci</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>1187</volume>
            <fpage>101</fpage>
            <page-range>101-21</page-range>
            <pub-id pub-id-type="pmid">20201848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17478.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Docherty</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives.</article-title>
            <source>Br J Pharmacol</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>160</volume>
            <issue>5</issue>
            <fpage>1029</fpage>
            <page-range>1029-44</page-range>
            <pub-id pub-id-type="pmid">20590597</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17478.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richards</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Albertson</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Derlet</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Horowitz</surname>
                <given-names>BZ</given-names>
              </name>
            </person-group>
            <article-title>Treatment of toxicity from amphetamines, related derivatives, and analogues: a systematic clinical review.</article-title>
            <source>Drug Alcohol Depend</source>
            <year>2015</year>
            <month>May</month>
            <day>01</day>
            <volume>150</volume>
            <fpage>1</fpage>
            <page-range>1-13</page-range>
            <pub-id pub-id-type="pmid">25724076</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
